Phase III trial of VM202 in the patient with critical limb ischemia (CLI).
Phase of Trial: Phase III
Latest Information Update: 28 Jun 2019
Price : $35 *
At a glance
- Drugs Donaperminogene seltoplasmid (Primary)
- Indications Peripheral arterial disorders; Peripheral ischaemia
- Focus Therapeutic Use
- 17 Nov 2017 New trial record
- 12 Nov 2017 According to a ViroMed media release, IND has been approved by the China Food and Drug Administration.